Free Trial

Processa Pharmaceuticals (PCSA) Competitors

Processa Pharmaceuticals logo
$0.24 +0.00 (+0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$0.24 +0.00 (+0.66%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCSA vs. APM, KLTO, DRMA, TTNP, TCRT, CDT, EVOK, ONCO, CMND, and SONN

Should you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Aptorum Group (APM), Klotho Neurosciences (KLTO), Dermata Therapeutics (DRMA), Titan Pharmaceuticals (TTNP), Alaunos Therapeutics (TCRT), Conduit Pharmaceuticals (CDT), Evoke Pharma (EVOK), Onconetix (ONCO), Clearmind Medicine (CMND), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical products" industry.

Processa Pharmaceuticals vs.

Processa Pharmaceuticals (NASDAQ:PCSA) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 13.0% of Processa Pharmaceuticals shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Processa Pharmaceuticals currently has a consensus price target of $6.00, indicating a potential upside of 2,365.08%. Given Processa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Processa Pharmaceuticals is more favorable than Aptorum Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Processa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aptorum Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aptorum Group received 26 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.33% of users gave Aptorum Group an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Processa PharmaceuticalsOutperform Votes
15
60.00%
Underperform Votes
10
40.00%
Aptorum GroupOutperform Votes
41
68.33%
Underperform Votes
19
31.67%

Aptorum Group has higher revenue and earnings than Processa Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Processa PharmaceuticalsN/AN/A-$11.12M-$3.08-0.08
Aptorum Group$430K10.70-$2.83MN/AN/A

Aptorum Group's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Processa PharmaceuticalsN/A -195.21% -163.06%
Aptorum Group N/A N/A N/A

In the previous week, Processa Pharmaceuticals' average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score.

Company Overall Sentiment
Processa Pharmaceuticals Neutral
Aptorum Group Neutral

Processa Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Aptorum Group has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500.

Summary

Aptorum Group beats Processa Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Processa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCSA vs. The Competition

MetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.89M$6.49B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.079.1826.8919.71
Price / SalesN/A252.26386.75120.59
Price / CashN/A65.8538.2534.62
Price / Book0.066.456.774.50
Net Income-$11.12M$144.21M$3.23B$248.22M
7 Day Performance-1.46%2.46%1.82%0.56%
1 Month Performance10.34%4.59%11.12%13.17%
1 Year Performance-86.77%-2.68%17.09%7.30%

Processa Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCSA
Processa Pharmaceuticals
3.0697 of 5 stars
$0.24
+1.0%
$6.00
+2,365.1%
-87.3%$2.89MN/A-0.0720
APM
Aptorum Group
0.354 of 5 stars
$0.93
+7.9%
N/A-76.6%$4.97M$430,000.000.0030Positive News
KLTO
Klotho Neurosciences
N/A$0.17
+5.0%
N/AN/A$4.89MN/A0.00N/APositive News
Earnings Report
High Trading Volume
DRMA
Dermata Therapeutics
1.3163 of 5 stars
$0.79
-2.0%
$6.00
+655.7%
-77.5%$4.79MN/A-0.058Positive News
Analyst Forecast
TTNP
Titan Pharmaceuticals
0.19 of 5 stars
$5.23
+2.8%
N/A-31.7%$4.78M$180,000.00-1.0010Analyst Forecast
Gap Up
TCRT
Alaunos Therapeutics
1.1132 of 5 stars
$2.85
flat
N/A-76.3%$4.67M$10,000.000.0040Positive News
Earnings Report
Gap Down
CDT
Conduit Pharmaceuticals
0.7041 of 5 stars
$0.41
+2.3%
N/A-99.9%$4.64MN/A-0.013News Coverage
Earnings Report
Stock Split
EVOK
Evoke Pharma
0.1066 of 5 stars
$3.11
-1.1%
N/A-36.3%$4.64M$10.25M-0.284Negative News
Gap Up
ONCO
Onconetix
0.0628 of 5 stars
$0.07
-2.8%
N/A-98.4%$4.52M$1.87M0.0012News Coverage
Positive News
Gap Up
CMND
Clearmind Medicine
0.1308 of 5 stars
$0.99
+2.2%
N/A-16.7%$4.21MN/A-0.53N/A
SONN
Sonnet BioTherapeutics
2.0584 of 5 stars
$1.33
+3.9%
$20.00
+1,403.8%
-27.3%$4.08M$1M0.0010

Related Companies and Tools


This page (NASDAQ:PCSA) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners